All updated as on -
Digital diabetes management market size is anticipated to grow at a 21.1% CAGR from 2023 to 2030, reaching USD 87.9 billion. By using advanced perfect models of cutting-edge innovations through clever glucose meters and blood glucose following applications, computerized diabetic executives assist diabetes patients in personalizing and monitoring their condition.
The surge in diabetes cases worldwide is being attributed to the fast evolving lifestyles, such as smoking and alcohol intake. Additionally, one of the main causes of diabetes is obesity. With the rising number of obese people and greater patient awareness, the market for diet and weight control apps is showing enormous promise.
Diabetes is a medical illness when the body's glucose levels rise as a result of the pancreas' failure to make insulin. The impact of food and activity on sugar levels, interpreting medical advice, and choosing what to eat are just a few of the daily issues faced by diabetic people. By communicating with the medical staff and exchanging data, patients may take care of their health issues thanks to the anytime, anywhere nature of digital technology. As a result, a digital ecosystem of data-driven solutions is developing that can link patients and the people providing their care for improved diabetes control.
The subject of artificial intelligence (AI) is rapidly expanding, and its applications in the treatment of diabetes have changed how this chronic condition is diagnosed and managed. Algorithms supporting predictive models for the risk of getting diabetes or its complications have been developed using machine learning principles. Resource usage in diabetes has been improved thanks to technological advancements. By reducing fasting and postprandial glucose levels, glucose excursions, and glycosylated hemoglobin, these clever technical innovations have improved glycemic management overall. With the use of AI, diabetes management will undergo a paradigm change from traditional management techniques to constructing targeted data-driven precision care. For instance, Livongo Health (US) uses a big data-enabled strategy to assist people in managing their health and enhancing their lifestyles. Many people use the business's cutting-edge goods, which include scales, blood pressure cuffs, and blood glucose meters that can gather data and transfer it to a bigger database. The organization then makes use of this data to produce thorough insights for the benefit of the patients.
A smartphone-connected insulin pump, for example, can cost between USD 4,500 and USD 6,500. Additionally, the cost of selling sensor-based continuous glucose monitors ranges from USD 1,000 to USD 1,400, with sensors needing to be changed every few days. Digital blood glucose meters for self-monitoring sell for between $15 and $20. For a considerable majority of end users, especially those in developing nations with unfavorable reimbursement scenarios, modern devices are out of reach due to the high initial cost and frequent use of associated consumables (requiring recurrent purchase). In wealthy nations, the majority of commercial health plans pay the cost of commercially marketed devices; but, in underdeveloped nations, discrepancies in reimbursement practices frequently lead to non-compliance with treatment. Diabetes patients in China and India must pay the full cost of insulin, integrated CGM systems, blood glucose monitors, and their upkeep. Therefore, it is projected that the adoption of digital diabetes management systems will be constrained in the upcoming years due to the high costs and lack of reimbursements in developing nations.
Diabetes is becoming more prevalent, which has increased interest in how things are going and in receiving better diabetes treatment solutions. Additionally, advances in technology have ensured the presentation of incredibly flexible solutions for those on the lookout. One of the other key factors promoting business sector development is the growing acceptance of cloud-based project arrangements and the expanding use of related devices and apps. However, issues including high device costs, a lack of payback in developing countries, and a higher acceptance of traditional diabetes management devices are expected to restrain the growth of this market throughout the forecast period.
Report Coverage
Global Digital Diabetes Management research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Digital Diabetes Management report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Digital Diabetes Management competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Digital Diabetes Management market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Digital Diabetes Management market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Digital Diabetes Management market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, Agamatrix, Inc., Ascensia Diabetes Care Holdings Ag., B. Braun Melsungen AG, Dariohealth Corporation, Dexcom, Inc., F. Hoffmann-La Roche, Glooko, Inc., Insulet Corporation, Lifescan, Inc., Medtronic PLC, Tandem Diabetes Care, Inc., Tidepool, BECTON, DICKINSON AND COMPANY, Bayer AG., ACON LABORATORIES, INC., NOVO NORDISK A/S, Terumo corporation.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Digital Diabetes Management market based on the below-mentioned segments:
Global Digital Diabetes Management Market, By Type
Wearable Devices
Handheld Devices
Global Digital Diabetes Management market, By Product and Service
DevicesSmart Glucose Meters
Smart Insulin Pens
Continuous Glucose Monitoring Systems
Smart Insulin Pumps/Closed Loop Systems & Smart Insulin Patches
Data Management Software and Platforms
Digital Diabetes Management AppsWeight & Diet Management Apps
Diabetes & Blood Glucose Tracking Apps
Services
Global Digital Diabetes Management Market, By End User
Homecare
Hospitals & Specialty Diabetes Clinics
Academic & Research Institutes
Others
Global Digital Diabetes Management market, Regional Analysis
The surge in diabetes cases worldwide is being attributed to the fast evolving lifestyles, such as smoking and alcohol intake. Additionally, one of the main causes of diabetes is obesity. With the rising number of obese people and greater patient awareness, the market for diet and weight control apps is showing enormous promise.
Diabetes is a medical illness when the body's glucose levels rise as a result of the pancreas' failure to make insulin. The impact of food and activity on sugar levels, interpreting medical advice, and choosing what to eat are just a few of the daily issues faced by diabetic people. By communicating with the medical staff and exchanging data, patients may take care of their health issues thanks to the anytime, anywhere nature of digital technology. As a result, a digital ecosystem of data-driven solutions is developing that can link patients and the people providing their care for improved diabetes control.
The subject of artificial intelligence (AI) is rapidly expanding, and its applications in the treatment of diabetes have changed how this chronic condition is diagnosed and managed. Algorithms supporting predictive models for the risk of getting diabetes or its complications have been developed using machine learning principles. Resource usage in diabetes has been improved thanks to technological advancements. By reducing fasting and postprandial glucose levels, glucose excursions, and glycosylated hemoglobin, these clever technical innovations have improved glycemic management overall. With the use of AI, diabetes management will undergo a paradigm change from traditional management techniques to constructing targeted data-driven precision care. For instance, Livongo Health (US) uses a big data-enabled strategy to assist people in managing their health and enhancing their lifestyles. Many people use the business's cutting-edge goods, which include scales, blood pressure cuffs, and blood glucose meters that can gather data and transfer it to a bigger database. The organization then makes use of this data to produce thorough insights for the benefit of the patients.
A smartphone-connected insulin pump, for example, can cost between USD 4,500 and USD 6,500. Additionally, the cost of selling sensor-based continuous glucose monitors ranges from USD 1,000 to USD 1,400, with sensors needing to be changed every few days. Digital blood glucose meters for self-monitoring sell for between $15 and $20. For a considerable majority of end users, especially those in developing nations with unfavorable reimbursement scenarios, modern devices are out of reach due to the high initial cost and frequent use of associated consumables (requiring recurrent purchase). In wealthy nations, the majority of commercial health plans pay the cost of commercially marketed devices; but, in underdeveloped nations, discrepancies in reimbursement practices frequently lead to non-compliance with treatment. Diabetes patients in China and India must pay the full cost of insulin, integrated CGM systems, blood glucose monitors, and their upkeep. Therefore, it is projected that the adoption of digital diabetes management systems will be constrained in the upcoming years due to the high costs and lack of reimbursements in developing nations.
Diabetes is becoming more prevalent, which has increased interest in how things are going and in receiving better diabetes treatment solutions. Additionally, advances in technology have ensured the presentation of incredibly flexible solutions for those on the lookout. One of the other key factors promoting business sector development is the growing acceptance of cloud-based project arrangements and the expanding use of related devices and apps. However, issues including high device costs, a lack of payback in developing countries, and a higher acceptance of traditional diabetes management devices are expected to restrain the growth of this market throughout the forecast period.
Report Coverage
Global Digital Diabetes Management research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Digital Diabetes Management report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Digital Diabetes Management competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Digital Diabetes Management market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Abbott Laboratories, Agamatrix, Inc., Ascensia Diabetes Care Holdings Ag., B. Braun Melsungen AG, Dariohealth Corporation, Dexcom, Inc., F. Hoffmann-La Roche, Glooko, Inc., Insulet Corporation, Lifescan, Inc., Medtronic PLC, Tandem Diabetes Care, Inc., Tidepool, BECTON, DICKINSON AND COMPANY, Bayer AG., ACON LABORATORIES, INC., NOVO NORDISK A/S, Terumo corporation. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Digital Diabetes Management Market from 2021 to 2030.
- Market Forecast for Digital Diabetes Management Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Digital Diabetes Management competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Digital Diabetes Management
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Digital Diabetes Management market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Digital Diabetes Management market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, Agamatrix, Inc., Ascensia Diabetes Care Holdings Ag., B. Braun Melsungen AG, Dariohealth Corporation, Dexcom, Inc., F. Hoffmann-La Roche, Glooko, Inc., Insulet Corporation, Lifescan, Inc., Medtronic PLC, Tandem Diabetes Care, Inc., Tidepool, BECTON, DICKINSON AND COMPANY, Bayer AG., ACON LABORATORIES, INC., NOVO NORDISK A/S, Terumo corporation.
Primary Target Market
- Market Players of Digital Diabetes Management
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Digital Diabetes Management market based on the below-mentioned segments:
Global Digital Diabetes Management Market, By Type
Wearable Devices
Handheld Devices
Global Digital Diabetes Management market, By Product and Service
DevicesSmart Glucose Meters
Smart Insulin Pens
Continuous Glucose Monitoring Systems
Smart Insulin Pumps/Closed Loop Systems & Smart Insulin Patches
Data Management Software and Platforms
Digital Diabetes Management AppsWeight & Diet Management Apps
Diabetes & Blood Glucose Tracking Apps
Services
Global Digital Diabetes Management Market, By End User
Homecare
Hospitals & Specialty Diabetes Clinics
Academic & Research Institutes
Others
Global Digital Diabetes Management market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive digital diabetes management market market research and competitor analysis for your business to help you develop more profound insights into the digital diabetes management market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the digital diabetes management market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.